Skip to main content

Table 4 Characterization of the responders to combined checkpoint blockade (n = 10)

From: Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

ResponseDuration of response (months)Time to response (weeks)Treatment cycles (induction + maintenance)GenderTime to metastasis from primary tumor (months)Age at treatment onset (years)Available molecular/ genetic analysisECOGLDHCRPRisk scorePrevious systemic treatmentPrevious liver-directed treatmentSites of metastasisAE ≥ grade 3 (CTCAE v5.0)
PR1454 + 0female946mutated: GNAQ (Q209P)0normalnormallownivolumab (PD)TACEliveryes (colitis)
PR9101 + 0female9254mutated: GNAQ (Q209P), ALK, MET; wildtype: BRAF, NRAS, GNA11, BAP10normalnormallownonenonelungyes (colitis)
PR23104 + 0female3377mutated: GNA110elevatedunknownlownonechemo-saturationliver, mesenteric fat tissueyes (Guillain-Barré syndrome)
PR55133 + 0male40867mutated: GNAQ0normalelevatedhighnonesurgeryliver, nodalyes (colitis, hypophysitis)
PR65194 + 0female16860mutated: GNAQ; wildtype: BRAF, NRAS, KIT, GNA110elevatednormalhighnoneTACEliver, lung, ovarial, cervix, omentumno
CR53124 + 5maleunknown59unknown0unknownunknownlownonesurgerylungno
CR50124 + 16maleunknown45unknown0elevatedelevatedvery highnonenoneliver, bone, pelvicno
PR26133 + 0female1467unknown0elevatednormalintermediatenoneSIRTliver, lungyes (uveitis)
PR25144 + 1female3056wildtype: BRAF, NRAS, KIT; expression PD-L1 20%; polysomia of chromosome 120elevatedelevatedhighnonenoneliver, lungno
PR11314 + 27female5373wildtype: BRAF, KIT, KRAS, NRAS, NF1, CDKN2A, CDK40elevatedunknownintermediatenonechemo-saturationliver, bone, nodal, renalno
  1. Abbreviations: CR Complete response, PR Partial response, ECOG Eastern Cooperative Oncology Group, LDH Lactate dehydrogenase, CRP C-reactive protein, TACE Transarterial chemoembolization, SIRT Selective internal radiation therapy, AE Adverse event(s), CTCAE Common Terminology Criteria for Adverse Events